Biogen Idec, Inc. (BIIB) Misses Q1 EPS by 8c; Guides FY12
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $200.05 +0.05%
Revenue Growth %: -6.5%
Financial Fact:
Selling, general and administrative: 462.7M
Today's EPS Names:
PLCE, COE, JVA, More
Revenue Growth %: -6.5%
Financial Fact:
Selling, general and administrative: 462.7M
Today's EPS Names:
PLCE, COE, JVA, More
Join SI Premium – FREE
Biogen Idec, Inc. (NASDAQ: BIIB) reported Q1 EPS of $1.40, $0.08 worse than the analyst estimate of $1.48. Revenue for the quarter came in at $1.29 billion versus the consensus estimate of $1.31 billion.
Sees FY12 adj-EPS above $6.15, which compares to the Street estimate of $6.19.
Expecting to buyback an additional $500 million in common shares.
For earnings history and earnings-related data on Biogen Idec, Inc. (BIIB) click here.
Sees FY12 adj-EPS above $6.15, which compares to the Street estimate of $6.19.
Expecting to buyback an additional $500 million in common shares.
For earnings history and earnings-related data on Biogen Idec, Inc. (BIIB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nvidia pitches Vera CPU to Chinese clients with August delivery target
- Sharon AI surges premarket; New Oriental gains, Medline slips
- UBS Reiterates Neutral Rating on Lennar (LEN) Following Q2 Results
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Earnings, Stock BuybacksRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
